Med BioGene Inks LungExpress Alliance with Precision Therapeutics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Med BioGene today said that it has signed a licensing agreement with Precision Therapeutics covering its LungExpress Dx gene expression-based test for lung cancer.

LungExpress has been developed to identify patients with early-stage non-small-cell lung cancer who, following surgical removal of their tumor, are at higher and lower risks of mortality.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.